Cover Image
市場調查報告書

腹瀉:開發中產品分析

Diarrhea - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192560
出版日期 內容資訊 英文 146 Pages
訂單完成後即時交付
價格
Back to Top
腹瀉:開發中產品分析 Diarrhea - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 146 Pages
簡介

腹瀉主要是由於不衛生條件所導致的接觸性傳染之胃腸感染病。腹瀉也可能與病毒或細菌感染有關,此外食物中毒也常是原因之一。其症狀有噁心、腹痛、肌肉痙攣、腫脹、脫水、發熱、血便、為了排便而處於頻繁的尿意及失禁等。治療法包含投藥療法及健康性的生活方式。

本報告網羅全球腹瀉治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等。

目錄

簡介

  • 分析範圍

腹瀉概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥 - 各企業

開發中的治療藥 - 大學/研究機關

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品 - 各企業

開發中的產品 - 大學/研究機關

治療藥的開發企業

  • Ipsen S.A.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Shire Plc
  • Mucosis B.V
  • Helsinn Healthcare S.A.
  • Ventria Bioscience.
  • Ache Laboratorios Farmaceuticos S/A
  • Ocera Therapeutics, Inc.
  • GP Pharm, S.A.
  • Tioga Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Aegis Therapeutics, LLC
  • Drais Pharmaceuticals, Inc.
  • DesignMedix, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Rottapharm¦Madaus
  • Sanofi Pasteur SA
  • Inhibikase Therapeutics, Inc.
  • Rebiotix Inc

治療藥的評估

  • 單劑治療藥
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 產品概要
  • 作用機制
  • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9525IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 10, 2, 1, 21 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diarrhea - Overview
    • Diarrhea - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Diarrhea - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Diarrhea - Companies Involved in Therapeutics Development
    • A. Menarini Industrie Farmaceutiche Riunite Srl
    • Actelion Ltd
    • Aegis Therapeutics LLC
    • Akthelia Pharmaceuticals Ltd
    • Albireo Pharma Inc
    • Allergan Plc
    • Anatara Lifesciences Limited
    • Ardelyx Inc
    • Assembly Biosciences Inc
    • AzurRx BioPharma Inc
    • Bharat Biotech International Ltd
    • Cosmo Pharmaceuticals NV
    • DiscoveryBiomed Inc
    • GP Pharm SA
    • Miyarisan Pharmaceutical Company Ltd
    • Mucosis BV
    • Napo Pharmaceuticals Inc
    • Nippon Shinyaku Co Ltd
    • Novartis AG
    • Pfizer Inc
    • Prokarium Ltd
    • Rebiotix Inc
    • Recce Ltd
    • RedHill Biopharma Ltd
    • RxBio Inc
    • Scandinavian Biopharma Holding AB
    • Sigmoid Pharma Ltd
    • Summit Therapeutics Plc
    • Synthetic Biologics Inc
    • Syntiron LLC
    • Tasly Pharmaceutical Group Co Ltd
    • Wuhan Institute of Biological Products Co Ltd
  • Diarrhea - Drug Profiles
    • ABIM-101 - Drug Profile
    • AKT-10081 - Drug Profile
    • ASP-7147 - Drug Profile
    • AZX-1101 - Drug Profile
    • Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
    • cadazolid - Drug Profile
    • Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile
    • CBM-588 - Drug Profile
    • cholestyramine - Drug Profile
    • crofelemer DR - Drug Profile
    • Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile
    • Escherichia coli vaccine - Drug Profile
    • ETEC vaccine - Drug Profile
    • ETEC vaccine - Drug Profile
    • Etvax - Drug Profile
    • GXG-8 - Drug Profile
    • ibodutant - Drug Profile
    • IMSUTMR-1501 - Drug Profile
    • infectious diarrhea [serotype H11] vaccine - Drug Profile
    • LJN-452 - Drug Profile
    • octreotide acetate - Drug Profile
    • octreotide acetate MAR - Drug Profile
    • ondansetron hydrochloride CR - Drug Profile
    • ORP-101 - Drug Profile
    • Peptide to Activate NHE-3 for Diarrhea - Drug Profile
    • PF-06425090 - Drug Profile
    • prulifloxacin - Drug Profile
    • PZ-7475 - Drug Profile
    • RBX-2660 - Drug Profile
    • RDX-023 - Drug Profile
    • RDX-98940 - Drug Profile
    • RECCE-355 - Drug Profile
    • Recombinant Enzyme for Diarrhea - Drug Profile
    • ribaxamase - Drug Profile
    • ridinilazole - Drug Profile
    • rifamycin CR - Drug Profile
    • Rotavac-5C - Drug Profile
    • rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile
    • Rx-100 - Drug Profile
    • Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
    • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
    • Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile
    • SYN-006 - Drug Profile
    • SYN-007 - Drug Profile
    • thuricin CD - Drug Profile
    • Typhetec - Drug Profile
    • Vaccine 1 for Diarrhea - Drug Profile
    • Vaccine 2 for Diarrhea - Drug Profile
    • Vaccine for Traveler's Diarrhea - Drug Profile
    • Vaccine for Traveler's Diarrhea - Drug Profile
    • Yersinia pestis vaccine - Drug Profile
  • Diarrhea - Dormant Projects
  • Diarrhea - Discontinued Products
  • Diarrhea - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diarrhea, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017
  • Diarrhea - Pipeline by Actelion Ltd, H2 2017
  • Diarrhea - Pipeline by Aegis Therapeutics LLC, H2 2017
  • Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2017
  • Diarrhea - Pipeline by Albireo Pharma Inc, H2 2017
  • Diarrhea - Pipeline by Allergan Plc, H2 2017
  • Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2017
  • Diarrhea - Pipeline by Ardelyx Inc, H2 2017
  • Diarrhea - Pipeline by Assembly Biosciences Inc, H2 2017
  • Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2017
  • Diarrhea - Pipeline by Bharat Biotech International Ltd, H2 2017
  • Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2017
  • Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2017
  • Diarrhea - Pipeline by GP Pharm SA, H2 2017
  • Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017
  • Diarrhea - Pipeline by Mucosis BV, H2 2017
  • Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2017
  • Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
  • Diarrhea - Pipeline by Novartis AG, H2 2017
  • Diarrhea - Pipeline by Pfizer Inc, H2 2017
  • Diarrhea - Pipeline by Prokarium Ltd, H2 2017
  • Diarrhea - Pipeline by Rebiotix Inc, H2 2017
  • Diarrhea - Pipeline by Recce Ltd, H2 2017
  • Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2017
  • Diarrhea - Pipeline by RxBio Inc, H2 2017
  • Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2017
  • Diarrhea - Pipeline by Sigmoid Pharma Ltd, H2 2017
  • Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2017
  • Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2017
  • Diarrhea - Pipeline by Syntiron LLC, H2 2017
  • Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
  • Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2017
  • Diarrhea - Dormant Projects, H2 2017
  • Diarrhea - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Diarrhea - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Diarrhea - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Diarrhea, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top